{
    "clinical_study": {
        "@rank": "152922", 
        "brief_summary": {
            "textblock": "A certain molecule floating in the blood may represent a risk of lung injury after a\n      transfusion.  We are determining whether detection of this molecule on a simple blood\n      clotting test will predict the development of lung injury due to transfusion in bleeding\n      patients with chronic liver disease."
        }, 
        "brief_title": "Predicting Lung Injury From Transfusion in Patients With Liver Disease", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Transfusion-related Acute Lung Injury", 
            "Chronic Liver Disease", 
            "Gastrointestinal Bleeding"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastrointestinal Hemorrhage", 
                "Hemorrhage", 
                "Liver Diseases", 
                "Acute Lung Injury", 
                "Respiratory Distress Syndrome, Adult", 
                "Lung Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:  Subjects will be eligible to participate in the study if they meet\n        all of the following criteria:\n\n          1. Admit to an ICU due to gastrointestinal bleeding AND an INR > 1.5\n\n          2. Patient has chronic liver disease defined as 1 or more of the three following\n             diagnostic criteria:\n\n               1. Previous diagnosis of chronic liver disease OR Imaging or biopsy diagnosis of\n                  cirrhosis\n\n               2. Signs of portal hypertension (ascites, varices, hypersplenism)\n\n               3. Laboratory evidence of synthetic dysfunction (INR>1.5, Bilirubin> 2.0, Albumin<\n                  2.5) AND \u22652 physical exam findings on admission associated with chronic liver\n                  disease (palmar erythema, spider angiomata, asterixis, caput medusa,\n                  gynecomastia)\n\n        Exclusion criteria: Subjects will be ineligible to participate in the study if they meet\n        any of the following criteria\n\n          1. Patient under age 18 OR pregnant OR incarcerated\n\n          2. Patient meets criteria for acute respiratory distress syndrome (ARDS) (PaO2/FiO2<165)\n\n          3. Patient admitted to ICU for re-bleed on same hospital admission OR has already\n             received >4 units of plasma.\n\n          4. History of inheritable or acquired clotting or bleeding disorder\n\n          5. Patient actively anticoagulated or has recently received (within 72h) vitamin K\n             antagonists, direct thrombin inhibitors, heparins or Xa antagonists"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patient with chronic Liver disease admitted to an intensive care unit with a\n        gastrointestinal bleed and INR> 1.5 who may receive plasma transfusion therapy."
            }
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756690", 
            "org_study_id": "09-0238"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "respiratory distress syndrome, adult", 
            "blood component transfusion", 
            "gastrointestinal hemorrhage", 
            "blood coagulation"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Denver, Anshutz medical campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80207"
                    }, 
                    "name": "Denver Health and Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Endogenous Heparinoid Interference With Coagulation on Thromboelastogram as a Predictive Biomarker for Transfusion Related Acute Lung Injury (TRALI)", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "TRALI (consensus definition- with exception of absence of other acute lung injury risk factors)", 
            "safety_issue": "No", 
            "time_frame": "0-54 hours post enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756690"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in ratio of partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)", 
                "safety_issue": "No", 
                "time_frame": "0-54 hours post enrollment"
            }, 
            {
                "description": "Baveno V criteria", 
                "measure": "Bleeding complications", 
                "safety_issue": "No", 
                "time_frame": "0-5 days post-enrollmnet"
            }
        ], 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014", 
        "why_stopped": "Recruitment"
    }
}